BAYLOR GENETICS


Associated tags: Baylor College of Medicine, Genetics, Texas Medical Center, NIH, Genetic testing, Patient, Whole genome sequencing, DSM-IV codes, Sequence, WGS, WES, Clinical trial, Genome, Gene, Diagnosis, Disease, Baylor, Phenotype, Medicine

Locations: TEXAS, HOUSTON, TX, US, BAYLOR, CANADA

Using AI to Improve Diagnosis of Rare Genetic Disorders

Retrieved on: 
Thursday, April 25, 2024
Genetics, Bangladesh Technical Education Board, Undiagnosed Diseases Network, UDN, NRI, Human Genome Sequencing Center, Hope, Hospital, Genetic disorder, DSM-IV codes, AIM, Pediatrics, Jan, Artificial intelligence, Intelligence, Disease, Human, Data, Baylor College of Medicine, Neurology, NEJM, Database, Diagnosis, Algorithm, Baylor University, Gene, DDD, Vaccine

The team developed a machine learning system called AI-MARRVEL (AIM) to help prioritize potentially causative variants for Mendelian disorders.

Key Points: 
  • The team developed a machine learning system called AI-MARRVEL (AIM) to help prioritize potentially causative variants for Mendelian disorders.
  • “The diagnostic rate for rare genetic disorders is only about 30%, and on average, it is six years from the time of symptom onset to diagnosis.
  • AIM is trained using a public database of known variants and genetic analysis called Model organism Aggregated Resources for Rare Variant ExpLoration ( MARRVEL ) previously developed by the Baylor team .
  • “AIM is a major step forward in using AI to diagnose rare diseases.

Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024

Retrieved on: 
Monday, March 4, 2024
Phenotype, Breakfast, Informatics, EST, Booth, Exome, Common, Nursing care plan, Down syndrome, Genetics, American College, ACMG, Genetic testing, M.D, Automation, Medical genetics, Transcriptome, Research, Whole genome sequencing, Pharmaceutical industry

HOUSTON, March 04, 2024 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will showcase its latest advancements and research discoveries at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting on March 12-16 in Toronto, Canada.

Key Points: 
  • The presentations shed light on cutting-edge developments in genetic analysis, diagnostic interpretation, and clinical results, underscoring Baylor Genetics’ mission to translate scientific innovation into accessible clinical solutions that improve patient outcomes and advance precision diagnostics.
  • "These presentations reflect our ongoing commitment to advancing the field of genetics and empowering patients, providers, and partners with insights and innovations to transform healthcare and improve lives."
  • Customers and partners interested in attending the breakfast can request an invitation and register here or inquire onsite at the Baylor Genetics booth.
  • Learn more about ACMG’s Annual Clinical Genetics Meeting through the conference website and visit the Baylor Genetics’ website to explore the company’s genetic testing capabilities.

Baylor Genetics Chief Medical Officer Christine Eng, M.D., Shares Sequencing Approaches for Undiagnosed Patients at Precision Medicine World Conference 2024

Retrieved on: 
Tuesday, January 23, 2024
Silicon, Whole genome sequencing, M.D, Patient, DSM-IV codes, Harvard University, Intensive care medicine, NICU, Baylor College of Medicine, Gene, WGS, Blog, Genetics, WES, Genetic testing, PICU, Conference, NIH, Sequence, Genome, Clinical trial, Bangladesh Technical Education Board, Hall, Diagnosis, UDN

Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).

Key Points: 
  • Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).
  • Baylor Genetics and partner Baylor College of Medicine have served as the sole sequencing core for UDN since its inception in 2014, providing WGS/WES testing, interpretation, validation and reporting for patients with rare genetic diseases.
  • The Harvard Gazette recently published one such story, noted in a Baylor Genetics blog on navigating the maze of undiagnosed diseases.
  • Learn more about PMWC through the conference website and visit the Baylor Genetics website to explore the company’s full spectrum of genetic testing capabilities.

Baylor Genetics Accelerates Growth, Combines Clinical and Scientific Expertise with Commercial Capabilities to Meet Increased Needs of Patients, Providers and Partners

Retrieved on: 
Wednesday, January 3, 2024
Cancer, Medicine, Treatment, Sequence, Epilepsy, Hospital, Genetics, AI, Calendar, UDN, DSM-IV codes, Texas Medical Center, Bangladesh Technical Education Board, Whole genome sequencing, Genetic testing, Growth, NIH, Patient, WES, Nursing care plan, WGS, Nursing

HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, continued to accelerate its market leadership and growth over the last 12 months, expanding its test menu, commercial reach, lab operations, technology, and customer experience initiatives.

Key Points: 
  • “Baylor Genetics saw strong double-digit growth in the 2023 calendar year, serving a growing roster of top children’s hospitals, leading health systems and partners,” said Kengo Takishima, President and Chief Executive Officer at Baylor Genetics.
  • “With more than 4 million tests performed to date, we are converting scientific innovation into accessible clinical solutions to help transform healthcare and unlock the power of precision medicine.
  • With the analytical expertise of 25 ABMGG-certified clinical lab directors, the lab is designed with multi-omics testing capabilities, scalable automated workflows, advanced robotics, AI, and predictive analytics.
  • Baylor Genetics doubled its commercial team to reach more customers nationwide while adding several new managed care contracts covering an additional 10 million lives.

Baylor Genetics to Present Scientific Research Findings at Upcoming NORD, NSGC and ASHG Conferences

Retrieved on: 
Monday, October 2, 2023

Christina Settler, Vice President, Medical Affairs, and Carli Andrews, Medical Science Liaison at Baylor Genetics will present findings from three accepted abstracts.

Key Points: 
  • Christina Settler, Vice President, Medical Affairs, and Carli Andrews, Medical Science Liaison at Baylor Genetics will present findings from three accepted abstracts.
  • Baylor Genetics reviewed internal data, ordering and reporting practices for secondary findings on WES and WGS tests from 15 US-based laboratories.
  • These will be presented by Qin Sun, Ph.D., Senior Division Director of Biochemical Genetics at Baylor Genetics; Hongzheng Dai, Ph.D., Associate Clinical Director NGS/Molecular, Baylor Genetics; Matthew Chau, Fellow, Clinical Genomics, Baylor Genetics; Weimin Bi, Ph.D., Division Director, Cytogenetics, Baylor Genetics, and Janice Smith, Ph.D., Senior Clinical Director, Cytogenetics, Baylor Genetics.
  • To learn more about Baylor Genetics, come see us at ASHG (booth 1826), NSGC (booth 200) and NORD (booth 322), or visit baylorgenetics.com .

Baylor Genetics Announces Neurodevelopmental Disorders Test Panel to Help Healthcare Providers Diagnose Patients with Intellectual Disabilities or Developmental Delays

Retrieved on: 
Tuesday, September 12, 2023
Cognition, Baylor, Communication, Spectrum, Catalog, Genomics, Autism spectrum, Clinical trial, Neurodevelopmental disorder, Prognosis, Brain, Disorder, Behavior, Intellectual disability, Genetics, DSM-IV codes, HIV disease progression rates, MD, Patient, Physician, Child, Development of the nervous system, WGS, Genetic testing, Diagnosis, Medical genetics, Research, American College, WES, Phenotype, Gene, Whole genome sequencing, Pediatrics, American College of Medical Genetics and Genomics, Sequence, Genome, Disease, Vaccine

The panel analyzes a clinically curated and targeted set of 236 genes to help healthcare providers and patients achieve a prompt, accurate genetic diagnosis and a better understanding of prognosis and anticipated disease progression.

Key Points: 
  • The panel analyzes a clinically curated and targeted set of 236 genes to help healthcare providers and patients achieve a prompt, accurate genetic diagnosis and a better understanding of prognosis and anticipated disease progression.
  • Baylor Genetics leveraged its genetic expertise and robust datasets to create the Neurodevelopmental Disorders Panel, which joins a growing catalog of disease-specific panels.
  • The panel is performed on an exome backbone capable of extracting a specific subset of genes for clinical reporting.
  • If panel results are negative, healthcare providers may request Whole Exome Sequencing allowing for broader analysis to help make a genetic diagnosis.

Baylor Genetics Announces Epilepsy Panel

Retrieved on: 
Tuesday, July 11, 2023
Epilepsy, Baylor, Charcot–Marie–Tooth disease, DNA, Health care, CDKL5 deficiency disorder, Clinical trial, Rett syndrome, Angelman syndrome, DSM-IV codes, CDKL5, Genetics, Genome, Patient, Blood, Medicine, DEE, Seizure, Genetic testing, Diagnosis, Phenotype, Gene, Character, Whole genome sequencing, Skin, Sequence, Saliva, Disease, SLC6A1 epileptic encephalopathy, Pharmaceutical industry

HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of an Epilepsy Panel and a STAT Epilepsy Panel - with the latter intended for patients with new onset or change in seizure frequency or character.

Key Points: 
  • HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of an Epilepsy Panel and a STAT Epilepsy Panel - with the latter intended for patients with new onset or change in seizure frequency or character.
  • In addition to epilepsy, seen in the setting of syndromic disorders, the Baylor Genetics Epilepsy Panel offers an analysis of well-studied, actionable genes related to many non-syndromic epilepsy disorders.
  • Healthcare providers should consider ordering Baylor Genetics’ Epilepsy Panel for patients with syndromic or non-syndromic epilepsy of a suspected genetic origin.
  • Visit our convenient online ordering portal to order the new Epilepsy Panel or STAT Epilepsy Panel today.

Baylor Genetics Announces Neuromuscular Disorders Panel

Retrieved on: 
Monday, May 22, 2023
Baylor, Myopathy, NGS, Clinical trial, Prognosis, DSM-IV codes, Genetics, Whole genome sequencing, HIV disease progression rates, Genetic disorder, Patient, Physician, Medicine, Muscular dystrophy, WGS, Genetic testing, Genetic heterogeneity, Diagnosis, WES, Gene, Phenotype, Sequence, Genome, Disease, Vaccine, Medical device

In addition to panel testing, Baylor Genetics offers Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) -- two of the most comprehensive precision diagnostic tests -- backed by expert clinical support for actionable treatment guidance. WES is used to understand the cause of a patient's symptoms (phenotypes) or a disease, especially when faced with a nonspecific presentation that may not be captured in a single panel. It provides insights into all genes in the human body, ensuring a full understanding of most genetic disorders. WGS takes this a step further, providing insights into the entire human genome, including the regions between genes. This extensive analysis can significantly increase diagnostic yield over all other types of genetic testing, empowering physicians and patients to make the most informed decisions about future care, family planning, or clinical trial eligibility.

Key Points: 
  • HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of a Neuromuscular Disorders Panel (NGS Panel) .
  • Hereditary neuromuscular disorders can be difficult to accurately diagnose based on phenotype alone because of their inherent genetic heterogeneity.
  • Baylor Genetics’ Neuromuscular Disorders Panel assesses many genes based on a clinical indication to help clinicians and their patients achieve an accurate diagnosis sooner and have a better understanding of the prognosis and anticipated disease progression.
  • Visit our convenient online ordering portal to order the new Neuromuscular Disorders Panel today.

Baylor Genetics and SRL, Inc. Initiate Clinical Grade of Whole Exome and Genome Sequencing Technology Transfer

Retrieved on: 
Wednesday, December 29, 2021
National, Spotless Group Holdings, Baylor University, R&D, WES, Technology transfer, LLC, Medical research, BG, No, GLOBE, Texas Medical Center, Genetic testing, Partnership, CEO, NIH, CMO, R, Precision medicine, LTS, Patient, Whole genome sequencing, WGS, Japan Agency for Medical Research and Development, Exome sequencing, Technology, SRL, Genetics, D, Baylor College of Medicine, Pharmaceutical industry

"I am confident that this collaboration enables SRL to provide optimal clinical sequencing for Japanese patients by applying the world's best technology with Baylor Genetics," said Kazuya Omi, R&D Executive Officer at SRL.

Key Points: 
  • "I am confident that this collaboration enables SRL to provide optimal clinical sequencing for Japanese patients by applying the world's best technology with Baylor Genetics," said Kazuya Omi, R&D Executive Officer at SRL.
  • As part of the agreement, BG will transfer its knowledge of WES and WGS as clinical services to SRL with technical support to enhance the Japanese lab's capabilities.
  • The technology transfer is expected to start in 2022 with efforts to contribute towards precision medicine application in Japan.
  • To learn more about Baylor Genetics' Whole Exome Sequencing services, visit: https://www.baylorgenetics.com/whole-exome-sequencing/
    To learn more about Baylor Genetics' Whole Genome Sequencing services, visit: https://www.baylorgenetics.com/whole-genome-sequencing/

Baylor Genetics Launches Combination Test for COVID-19 and Influenza A and B; Multi-Panel Test Seeks to Address Dilemma of "Overlapping symptoms caused by Distinct Diseases."

Retrieved on: 
Tuesday, November 17, 2020
Baylor College of Medicine, Baylor, Coronavirus disease, National Institutes of Health, Articles, Health, Texas

"Baylor Genetics created the combination COVID-19 and flu test because the symptoms between the two are so similar, but the treatments are undeniably different," stated Kengo Takishima, President & Chief Executive Officer at Baylor Genetics.

Key Points: 
  • "Baylor Genetics created the combination COVID-19 and flu test because the symptoms between the two are so similar, but the treatments are undeniably different," stated Kengo Takishima, President & Chief Executive Officer at Baylor Genetics.
  • In response to the global pandemic, Baylor Genetics validated its first test for COVID-19 in June 2020.
  • Group Holdings, Inc. and Baylor College of Medicine, including the #1 NIH-funded Department of Molecular and Human Genetics.
  • Located in Houston's Texas Medical Center, Baylor Genetics serves clients in 50 states and 16 countries.